文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

双能量网格头端消融系统治疗持续性心房颤动:一项随机试验

Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial.
PubMed 文献 · Nat Med · 2024-05-17

这项随机、单盲、非劣效性试验纳入420例持续性心房颤动患者,比较大型头端双脉冲场与射频能量导管消融与常规射频消融系统的效果。主要有效性复合终点在试验组和对照组分别为73.8%和65.8%(非劣效性P<0.0001),主要安全性复合终点方面试验组3例、对照组2例发生重大操作或器械相关并发症(非劣效性P<0.0001),试验组手术时间更短(P<0.0001)。

要点

  • 持续性房颤患者使用双能量网格头端导管消融,主要有效性复合终点非劣效于常规射频消融。
  • 试验组73.8% vs 对照组65.8%达到主要有效性复合终点(非劣效性P<0.0001)。
  • 重大操作或器械相关并发症试验组3例 vs 对照组2例,非劣效性P<0.0001。

核心结论

  • 双能量导管治疗持续性心房颤动在安全性和有效性上非劣效于常规射频消融系统。
  • 未来需要大规模研究收集真实世界证据,以评估聚焦双能量网格导管对更广泛房颤患者人群的影响。

研究设计与样本

  • 随机、单盲、非劣效性试验,纳入420例持续性心房颤动患者。
  • 患者接受大型头端双脉冲场与射频能量导管消融(试验组)或常规射频消融系统(对照组)。

主要发现

  • 主要有效性复合终点(包括无急性操作失败和任何时间重复消融,以及3个月空白期后无心律失常复发、无药物起始或升级、无电复律)在试验组为73.8%,对照组为65.8%(非劣效性P<0.0001)。
  • 主要安全性终点(无严重操作相关或器械相关不良事件复合终点)方面,试验组3例、对照组2例发生重大操作或器械相关并发症(非劣效性P<0.0001)。
  • 次要分析中,试验组手术时间短于对照组(P<0.0001)。

局限性

  • 未来需要大规模研究收集真实世界证据,以评估聚焦双能量网格导管对更广泛房颤患者人群的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical outcomes of catheter ablation for atrial fibrillation (AF) are suboptimal due, in part, to challenges in achieving durable lesions. Although focal point-by-point ablation allows for the creation of any required lesion set, this strategy necessitates the generation of contiguous lesions without gaps. A large-tip catheter, capable of creating wide-footprint ablation lesions, may increase ablation effectiveness and efficiency. In a randomized, single-blind, non-inferiority trial, 420 patients with persistent AF underwent ablation using a large-tip catheter with dual pulsed field and radiofrequency energies versus ablation using a conventional radiofrequency ablation system. The primary composite effectiveness endpoint was evaluated through 1 year and included freedom from acute procedural failure and repeat ablation at any time, plus arrhythmia recurrence, drug initiation or escalation or cardioversion after a 3-month blanking period. The primary safety endpoint was freedom from a composite of serious procedure-related or device-related adverse events. The primary effectiveness endpoint was observed for 73.8% and 65.8% of patients in the investigational and control arms, respectively (P < 0.0001 for non-inferiority). Major procedural or device-related complications occurred in three patients in the investigational arm and in two patients in the control arm (P < 0.0001 for non-inferiority). In a secondary analysis, procedural times were shorter in the investigational arm as compared to the control arm (P < 0.0001). These results demonstrate non-inferior safety and effectiveness of the dual-energy catheter for the treatment of persistent AF. Future large-scale studies are needed to gather real-world evidence on the impact of the focal dual-energy lattice catheter on the broader population of patients with AF. ClinicalTrials.gov identifier: NCT05120193 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Anter E, Mansour M, Nair DG, et al. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. Nat Med. 2024. PMID: 38760584. doi:10.1038/s41591-024-03022-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。